# FDA 483 - Paul W. Wallace, MD - March 17, 2026

Source: https://www.keypedia.com/records/483/paul-w-wallace-md/6412ed93-d955-4c0b-a44c-e8cf3b5a5cfa

> FDA 483 for Paul W. Wallace, MD on March 17, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Paul W. Wallace, MD
- Inspection Date: 2026-03-17
- Product Type: drugs
- Office Name: Los Angeles District Office
- Summary: An FDA inspection of Paul W. Wallace, MD in Los Angeles, CA, revealed significant deviations from investigational plans. The firm failed to complete numerous required procedures and assessments for multiple subjects across two protocols. Additionally, a large number of enrolled subjects missed all study visits due to personnel changes, indicating a severe lack of adherence to clinical trial protocols.

## Related Officers

- [Bruno Baltazar](https://www.keypedia.com/people/bruno-baltazar/95a94f09-6e24-4454-a18d-4cef89e721d9)
- [Jasmine Y. Wang](https://www.keypedia.com/people/jasmine-y-wang/e23c7335-477c-4671-8dcc-72e9149d424e)

Company: https://www.keypedia.com/companies/paul-w-wallace-md/c6e736a3-93ff-4b83-aa9d-86fb904877ca

Office: https://www.keypedia.com/offices/los-angeles-district-office/edcf1dfe-596a-43b8-8df4-07d9cd94763b